Attacking the supply wagons to starve cancer cells to death
Open accessThe DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
Abstract
The constitutive anabolism of cancer cells not only supports proliferation but also addicts tumor cells to a steady influx of exogenous nutrients. Limiting access to metabolic substrates could be an effective and selective means to block cancer growth. In this review, we define the pathways by which cancer cells acquire the raw materials for anabolism, highlight the actionable proteins in each pathway, and discuss the status of therapeutic interventions that disrupt nutrient acquisition. Critical open questions to be answered before apical metabolic inhibitors can be successfully and safely deployed in the clinic are also outlined. In summary, recent studies provide strong support that substrate limitation is a powerful therapeutic strategy to effectively, and safely, starve cancer cells to death.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma
Patel, A. P., Tirosh, I., Trombetta, J. J., Shalek, A. K., Gillespie, S. M., Wakimoto, H., Cahill, D. P., Nahed, B. V., Curry, W. T., Martuza, R. L., et al. (2014) · Science · doi:10.1126/science.1254257 · Cited by 5,063 · cited 1×
“However, tumor heterogeneity can limit the efficacy of these targeted agents [6–9].”
BackgroundCancer drug resistance: an evolving paradigm
Holohan, C., Van Schaeybroeck, S., Longley, D. B., & Johnston, P. G. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3599 · Cited by 4,681 · cited 2×
“In summary, metabolic inhibitors suffer from the same limitations as therapies targeting oncogenic signal transduction cascades [10–13].”
BackgroundMetabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate
Ward, P. S., & Thompson, C. B. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.014 · Cited by 3,233 · cited 1×
“As mentioned above, many excellent recent reviews describe how metabolic pathways are re-wired in cancer cells and the efforts to drug key enzymes in these pathways [1–5, 8, 19”
BackgroundCellular Fatty Acid Metabolism and Cancer
Currie, E., Schulze, A., Zechner, R., Walther, T. C., & Farese, R. V. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.05.017 · Cited by 2,123 · cited 3×
“How fatty acids enter cells is incompletely understood [119,121,122].”
BackgroundOncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism
Ying, H., Kimmelman, A. C., Lyssiotis, C. A., Hua, S., Chu, G. C., Fletcher-Sananikone, E., Locasale, J. W., Son, J., Zhang, H., Coloff, J. L., et al. (2012) · Cell · doi:10.1016/j.cell.2012.01.058 · Cited by 2,043
Wise, D. R., DeBerardinis, R. J., Mancuso, A., Sayed, N., Zhang, X.-Y., Pfeiffer, H. K., Nissim, I., Daikhin, E., Yudkoff, M., McMahon, S. B., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0810199105 · Cited by 2,001
The functions and regulation of the PTEN tumour suppressor
Song, M. S., Salmena, L., & Pandolfi, P. P. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3330 · Cited by 1,926
Bidirectional Transport of Amino Acids Regulates mTOR and Autophagy
Nicklin, P., Bergman, P., Zhang, B., Triantafellow, E., Wang, H., Nyfeler, B., Yang, H., Hild, M., Kung, C., Wilson, C., et al. (2009) · Cell · doi:10.1016/j.cell.2008.11.044 · Cited by 1,798
Macropinocytosis of protein is an amino acid supply route in Ras-transformed cells
Commisso, C., Davidson, S. M., Soydaner-Azeloglu, R. G., Parker, S. J., Kamphorst, J. J., Hackett, S., Grabocka, E., Nofal, M., Drebin, J. A., Thompson, C. B., et al. (2013) · Nature · doi:10.1038/nature12138 · Cited by 1,683
Metformin: from mechanisms of action to therapies
Foretz, M., Guigas, B., Bertrand, L., Pollak, M., & Viollet, B. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.09.018 · Cited by 1,501
Fasting: molecular mechanisms and clinical applications
Longo, V. D., & Mattson, M. P. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2013.12.008 · Cited by 1,425 · cited 1×
“Intermittent fasting schedules may be easier to adhere to than DR regimens yet produce many of the same benefits [216].”
BackgroundMetabolite profiling identifies a key role for glycine in rapid cancer cell proliferation
Jain, M., Nilsson, R., Sharma, S., Madhusudhan, N., Kitami, T., Souza, A. L., Kafri, R., Kirschner, M. W., Clish, C. B., & Mootha, V. K. (2012) · Science · doi:10.1126/science.1218595 · Cited by 1,403
The reverse Warburg effect: Aerobic glycolysis in cancer associated fibroblasts and the tumor stroma
Pavlides, S., Whitaker-Menezes, D., Castello-Cros, R., Flomenberg, N., Witkiewicz, A. K., Frank, P. G., Casimiro, M. C., Wang, C., Fortina, P., Addya, S., et al. (2009) · Cell Cycle · doi:10.4161/cc.8.23.10238 · Cited by 1,391
Goldstein, J. L., & Brown, M. S. (2009) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.108.179564 · Cited by 1,344 · cited 1×
“Most cholesterol is contained in low-density lipoprotein particles (LDL) and taken up by target cells expressing the LDL receptor (LDLr) (reviewed in [127,128], Figure 1).”
BackgroundThe role for autophagy in cancer
White, E. (2015) · Journal of Clinical Investigation · doi:10.1172/jci73941 · Cited by 1,332
The SLC2 (GLUT) family of membrane transporters
Mueckler, M., & Thorens, B. (2013) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2012.07.001 · Cited by 1,328
Metformin inhibits mitochondrial complex I of cancer cells to reduce tumorigenesis
Wheaton, W. W., Weinberg, S. E., Hamanaka, R. B., Soberanes, S., Sullivan, L. B., Anso, E., Glasauer, A., Dufour, E., Mutlu, G. M., Budigner, G. S., et al. (2014) · eLife · doi:10.7554/elife.02242 · Cited by 1,105 · cited 1×
“Indeed, limiting glucose is sufficient to sensitize some cancer cells to metformin [200] suggesting that metformin would be useful in combination with starvation agents that block nutrient uptake.”
BackgroundRational design and characterization of a Rac GTPase-specific small molecule inhibitor
Gao, Y., Dickerson, J. B., Guo, F., Zheng, J., & Zheng, Y. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0307512101 · Cited by 1,091 · cited 2×
“While not specific to the macropinocytosis pathway, the Rac1 GTPase and PAK serine threonine kinase are required for the Ras-dependent formation of macropinosomes, and inhibitors of both molecules are available [142,143,177].”
BackgroundBiological and therapeutic impact of intratumor heterogeneity in cancer evolution
McGranahan, N., & Swanton, C. (2015) · Cancer Cell · doi:10.1016/j.ccell.2014.12.001 · Cited by 1,077 · cited 2×
“However, tumor heterogeneity can limit the efficacy of these targeted agents [6–9].”
BackgroundIntracellular α-ketoglutarate maintains the pluripotency of embryonic stem cells
Carey, B. W., Finley, L. W. S., Cross, J. R., Allis, C. D., & Thompson, C. B. (2015) · Nature · doi:10.1038/nature13981 · Cited by 1,007
Serine starvation induces stress and p53-dependent metabolic remodelling in cancer cells
Maddocks, O. D. K., Berkers, C. R., Mason, S. M., Zheng, L., Blyth, K., Gottlieb, E., & Vousden, K. H. (2013) · Nature · doi:10.1038/nature11743 · Cited by 1,007 · cited 2×
“As mentioned earlier, the non-essential amino acids serine and glutamine are conditionally essential in some cancers [15,20].”
BackgroundShaping cups into phagosomes and macropinosomes
Swanson, J. A. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2447 · Cited by 941
Glucose Deprivation Contributes to the Development of KRAS Pathway Mutations in Tumor Cells
Yun, J., Rago, C., Cheong, I., Pagliarini, R., Angenendt, P., Rajagopalan, H., Schmidt, K., Willson, J. K. V., Markowitz, S., Zhou, S., et al. (2009) · Science · doi:10.1126/science.1174229 · Cited by 914
Acquired resistance to TKIs in solid tumours: learning from lung cancer
Camidge, D. R., Pao, W., & Sequist, L. V. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.104 · Cited by 862 · cited 1×
“…glutamine is utilized in cancers with different oncogenic mutations will be important to develop drug combinations that hit multiple steps in the same pathway, a strategy validated in B-Raf mutant melanomas treated with vemurafenib and MEK or ERK inhibitors and EGFR driven lung tumors [11,109,230].”
BackgroundSchug, Z. T., Peck, B., Jones, D. T., Zhang, Q., Grosskurth, S., Alam, I. S., Goodwin, L. M., Smethurst, E., Mason, S., Blyth, K., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2014.12.002 · Cited by 820 · cited 2×
“While under standard in vitro growth conditions 90% of acetyl CoA is derived from glucose or glutamine, a series of recent studies show that hypoxia and low nutrient conditions increase utilization of exogenous acetate for lipid synthesis and tumor growth [67–70].”
BackgroundTranscriptional control of autophagy-lysosome function drives pancreatic cancer metabolism
Perera, R. M., Stoykova, S., Nicolay, B. N., Ross, K. N., Fitamant, J., Boukhali, M., Lengrand, J., Deshpande, V., Selig, M. K., Ferrone, C. R., et al. (2015) · Nature · doi:10.1038/nature14587 · Cited by 799
Zhang, D.-W., Lagace, T. A., Garuti, R., Zhao, Z., McDonald, M., Horton, J. D., Cohen, J. C., & Hobbs, H. H. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m702027200 · Cited by 788 · cited 1×
“Alternatively, surface LDLr that is bound by PCKS9, a serine protease that is secreted by hepatocytes [130], is targeted to the lysosome for degradation.”
BackgroundCrystal structure of the human glucose transporter GLUT1
Deng, D., Xu, C., Sun, P., Wu, J., Yan, C., Hu, M., & Yan, N. (2014) · Nature · doi:10.1038/nature13306 · Cited by 777
Acetate is a bioenergetic substrate for human glioblastoma and brain metastases
Mashimo, T., Pichumani, K., Vemireddy, V., Hatanpaa, K. J., Singh, D. K., Sirasanagandla, S., Nannepaga, S., Piccirillo, S. G., Kovacs, Z., Foong, C., et al. (2014) · Cell · doi:10.1016/j.cell.2014.11.025 · Cited by 760 · cited 3×
“Oxidation of acetate occurs in both orthotopic glioma xenografts and brain metastases of other tumor types with a variety of oncogenic mutations [70].”
BackgroundTransformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation
Koivunen, P., Lee, S., Duncan, C. G., Lopez, G., Lu, G., Ramkissoon, S., Losman, J. A., Joensuu, P., Bergmann, U., Gross, S., et al. (2012) · Nature · doi:10.1038/nature10898 · Cited by 727 · cited 1×
“As metabolic reprogramming regulates stem cell fate and differentiation, CSCs might be forced to differentiate by metabolic therapies. α -ketoglutarate can maintain the undifferentiated state of embryonic stem cells in vitro [207], and alterations in metabolism can block differentiation [208].”
BackgroundKamphorst, J. J., Cross, J. R., Fan, J., de Stanchina, E., Mathew, R., White, E. P., Thompson, C. B., & Rabinowitz, J. D. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1307237110 · Cited by 726
MYC/PGC-1α Balance Determines the Metabolic Phenotype and Plasticity of Pancreatic Cancer Stem Cells
Sancho, P., Burgos-Ramos, E., Tavera, A., Bou Kheir, T., Jagust, P., Schoenhals, M., Barneda, D., Sellers, K., Campos-Olivas, R., Graña, O., et al. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.08.015 · Cited by 722 · cited 1×
“Pancreatic CSCs also exhibited an increased dependence on oxidative phosphorylation [206].”
BackgroundSmall Molecule Inhibition of the Autophagy Kinase ULK1 and Identification of ULK1 Substrates
Egan, D. F., Chun, M. G. H., Vamos, M., Zou, H., Rong, J., Miller, C. J., Lou, H. J., Raveendra-Panickar, D., Yang, C.-C., Sheffler, D. J., et al. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.05.031 · Cited by 715 · cited 2×
“Compound SBI-0206965 was directly compared to CQ and found to better potentiate the effect of mTORC inhibitors suggesting that ULK1/2 inhibitors may have greater therapeutic value [188].”
BackgroundMetabolic determinants of cancer cell sensitivity to glucose limitation and biguanides
Birsoy, K., Possemato, R., Lorbeer, F. K., Bayraktar, E. C., Thiru, P., Yucel, B., Wang, T., Chen, W. W., Clish, C. B., & Sabatini, D. M. (2014) · Nature · doi:10.1038/nature13110 · Cited by 710 · cited 1×
“It is noteworthy that the adaptive increase in oxidative phosphorylation with starvation [199] would be inhibited by metformin.”
BackgroundComerford, S. A., Huang, Z., Du, X., Wang, Y., Cai, L., Witkiewicz, A. K., Walters, H., Tantawy, M. N., Fu, A., Manning, H. C., et al. (2014) · Cell · doi:10.1016/j.cell.2014.11.020 · Cited by 681
Targeting the cancer kinome through polypharmacology
Knight, Z. A., Lin, H., & Shokat, K. M. (2010) · Nature reviews. Cancer · doi:10.1038/nrc2787 · Cited by 674 · cited 1×
“It is also intriguing to consider applying the concepts of polypharmacology to the cancer metabolism arena [231,232].”
BackgroundRaffaghello, L., Lee, C., Safdie, F. M., Wei, M., Madia, F., Bianchi, G., & Longo, V. D. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0708100105 · Cited by 587 · cited 1×
“Short term periods of starvation also reduce circulating IGF-1 levels, slow tumor progression [223,224], and protect normal cells from the toxic effects of chemotherapy [225].”
BackgroundTumor adaptation and resistance to RAF inhibitors
Lito, P., Rosen, N., & Solit, D. B. (2013) · Nature Medicine · doi:10.1038/nm.3392 · Cited by 585
AMPK modulates Hippo pathway activity to regulate energy homeostasis
Wang, W., Xiao, Z.-D., Li, X., Aziz, K. E., Gan, B., Johnson, R. L., & Chen, J. (2015) · Nature Cell Biology · doi:10.1038/ncb3113 · Cited by 549 · cited 1×
“GLUT3 is also ectopically expressed in liver and colorectal cancer where its expression is promoted by AMPK and YAP, a transcription factor that is negatively regulated by the Hippo tumor suppressor pathway [47].”
BackgroundA two-way street: reciprocal regulation of metabolism and signalling
Wellen, K. E., & Thompson, C. B. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3305 · Cited by 528 · cited 1×
“Protein glycosylation is altered in tumor cells [97], in part due to changes in metabolic wiring and glucose availability [98].”
BackgroundCell surface protein glycosylation in cancer
Christiansen, M. N., Chik, J., Lee, L., Anugraham, M., Abrahams, J. L., & Packer, N. H. (2014) · PROTEOMICS · doi:10.1002/pmic.201300387 · Cited by 518
Circumventing cancer drug resistance in the era of personalized medicine
Garraway, L. A., & Jänne, P. A. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0012 · Cited by 503 · cited 2×
“In summary, metabolic inhibitors suffer from the same limitations as therapies targeting oncogenic signal transduction cascades [10–13].”
BackgroundA highly potent and selective Vps34 inhibitor alters vesicle trafficking and autophagy
Ronan, B., Flamand, O., Vescovi, L., Dureuil, C., Durand, L., Fassy, F., Bachelot, M.-F., Lamberton, A., Mathieu, M., Bertrand, T., et al. (2014) · Nature Chemical Biology · doi:10.1038/nchembio.1681 · Cited by 500 · cited 1×
“Selective inhibitors for the class III PI3 kinase VPS34 also inhibit autophagy and may have similar effects to apilimod as PI3P produced by VPS34 is the substrate for PIKfyve [195].”
BackgroundTumours with PI3K activation are resistant to dietary restriction
Kalaany, N. Y., & Sabatini, D. M. (2009) · Nature · doi:10.1038/nature07782 · Cited by 468
AMPK: A Target for Drugs and Natural Products With Effects on Both Diabetes and Cancer
Hardie, D. G. (2013) · Diabetes · doi:10.2337/db13-0368 · Cited by 458 · cited 1×
“The anti-diabetic biguanide metformin is often discussed as a candidate component of metabolic combination therapies [196–198].”
BackgroundThe utilization of extracellular proteins as nutrients is suppressed by mTORC1
Palm, W., Park, Y., Wright, K., Pavlova, N. N., Tuveson, D. A., & Thompson, C. B. (2015) · Cell · doi:10.1016/j.cell.2015.06.017 · Cited by 457 · cited 4×
“This may limit their anti-tumor efficacy, particularly in Ras-driven cancers that sustain themselves through LDL uptake [137], macropinocytosis [165,166], and, in some contexts, autophagy (reviewed in [189]).”
BackgroundInfluentialGuillaumond, F., Bidaut, G., Ouaissi, M., Servais, S., Gouirand, V., Olivares, O., Lac, S., Borge, L., Roques, J., Gayet, O., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1421601112 · Cited by 454
Guo, D., Reinitz, F., Youssef, M., Hong, C., Nathanson, D., Akhavan, D., Kuga, D., Amzajerdi, A. N., Soto, H., Zhu, S., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0102 · Cited by 452 · cited 1×
“For example, LDLr expression driven by SREBP1, a transcription factor that is a master regulator of lipid metabolism downstream of PI3 kinase pathway signaling, contributes to glioblastoma growth [134].”
BackgroundHeterogeneity of tumor-induced gene expression changes in the human metabolic network
Hu, J., Locasale, J. W., Bielas, J. H., O'Sullivan, J., Sheahan, K., Cantley, L. C., Heiden, M. G. V., & Vitkup, D. (2013) · Nature Biotechnology · doi:10.1038/nbt.2530 · Cited by 407
Calorie restriction and cancer prevention: metabolic and molecular mechanisms
Longo, V. D., & Fontana, L. (2010) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2009.11.004 · Cited by 378 · cited 1×
“The molecular mechanisms underlying the tumor suppressive effects of DR are incompletely defined, but likely include increased resistance to oxidative stress and reductions in circulating growth factors such as IGF-1 and insulin that attenuate PI3 kinase pathway signaling [213,215,217–220].”
BackgroundActivity of the Monocarboxylate Transporter 1 Inhibitor AZD3965 in Small Cell Lung Cancer
Polański, R., Hodgkinson, C. L., Fusi, A., Nonaka, D., Priest, L., Kelly, P., Trapani, F., Bishop, P. W., White, A., Critchlow, S. E., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2270 · Cited by 378
Role of monocarboxylate transporters in human cancers: state of the art
Pinheiro, C., Longatto-Filho, A., Azevedo-Silva, J., Casal, M., Schmitt, F. C., & Baltazar, F. (2012) · Journal of Bioenergetics and Biomembranes · doi:10.1007/s10863-012-9428-1 · Cited by 368
Targeting ASCT2‐mediated glutamine uptake blocks prostate cancer growth and tumour development
Wang, Q., Hardie, R., Hoy, A. J., van Geldermalsen, M., Gao, D., Fazli, L., Sadowski, M. C., Balaban, S., Schreuder, M., Nagarajah, R., et al. (2015) · The Journal of Pathology · doi:10.1002/path.4518 · Cited by 338 · cited 2×
“ASCT2 shRNA inhibits the growth of prostate [91], breast [86], and two neuroblastoma xenografts [92] suggesting that ASCT2 inhibitors [93,94] could be effective in a subset of tumors.”
BackgroundShutes, A., Onesto, C., Picard, V., Leblond, B., Schweighoffer, F., & Der, C. J. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m703571200 · Cited by 336 · cited 1×
“While not specific to the macropinocytosis pathway, the Rac1 GTPase and PAK serine threonine kinase are required for the Ras-dependent formation of macropinosomes, and inhibitors of both molecules are available [142,143,177].”
BackgroundShroff, E. H., Eberlin, L. S., Dang, V. M., Gouw, A. M., Gabay, M., Adam, S. J., Bellovin, D. I., Tran, P. T., Philbrick, W. M., Garcia-Ocana, A., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1507228112 · Cited by 255
Kamphorst, J. J., Chung, M. K., Fan, J., & Rabinowitz, J. D. (2014) · Cancer & Metabolism · doi:10.1186/2049-3002-2-23 · Cited by 227
Phenothiazines induce PP2A-mediated apoptosis in T cell acute lymphoblastic leukemia
Gutierrez, A., Pan, L., Groen, R. W. J., Baleydier, F., Kentsis, A., Marineau, J., Grebliunaite, R., Kozakewich, E., Reed, C., Pflumio, F., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci65093 · Cited by 220
Catabolism of exogenous lactate reveals it as a legitimate metabolic substrate in breast cancer
Kennedy, K. M., Scarbrough, P. M., Ribeiro, A., Richardson, R., Yuan, H., Sonveaux, P., Landon, C. D., Chi, J.-T., Pizzo, S., Schroeder, T., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0075154 · Cited by 190
Vemurafenib resistance reprograms melanoma cells towards glutamine dependence
Hernandez-Davies, J. E., Tran, T. Q., Reid, M. A., Rosales, K. R., Lowman, X. H., Pan, M., Moriceau, G., Yang, Y., Wu, J., Lo, R. S., et al. (2015) · Journal of Translational Medicine · doi:10.1186/s12967-015-0581-2 · Cited by 131
Clathrin-independent endocytosis: A cargo-centric view
Maldonado-Báez, L., Williamson, C., & Donaldson, J. G. (2013) · Experimental Cell Research · doi:10.1016/j.yexcr.2013.08.008 · Cited by 97
Cited by
Li, S.-Y., Cheng, H., Xie, B.-R., Qiu, W.-X., Zeng, J.-Y., Li, C.-X., Wan, S.-S., Zhang, L., Liu, W.-L., & Zhang, X.-Z. (2017) · ACS Nano · doi:10.1021/acsnano.7b02533 · Cited by 780
Kim, S. M., Nguyen, T. T., Ravi, A., Kubiniok, P., Finicle, B. T., Jayashankar, V., Malacrida, L., Hou, J., Robertson, J., Gao, D., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1215 · Cited by 199
“4 INTRODUCTION Cancer cells up-regulate nutrient acquisition pathways to fuel oncogene-driven anabolism and proliferation (1).”
BackgroundMethodSelf-citationTargeting cancer metabolism by simultaneously disrupting parallel nutrient access pathways
Kim, S. M., Roy, S. G., Chen, B., Nguyen, T. M., McMonigle, R. J., McCracken, A. N., Zhang, Y., Kofuji, S., Hou, J., Selwan, E., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci87148 · Cited by 77
“As a single agent, SH-BC-893 acts like a combination therapy by targeting the multiple nutrient acquisition pathways that fuel cancer anabolism (17).”
BackgroundInfluentialSelf-citationHepowit, N. L., Moon, B., Ebert, A. C., Dickson, R. C., & MacGurn, J. A. (2023) · Journal of Cell Science · doi:10.1242/jcs.260675 · Cited by 18
Metadata
- Authors
- Selwan, E. M., Finicle, B. T., Kim, S. M., & Edinger, A. L.
- Venue
- FEBS Letters
- Publisher
- Wiley
- Published
- 2016-03-22
- Volume
- 590
- Issue
- 7
- Pages
- 885-907
- ISSN
- 0014-5793 (ISSN-L)
- 1873-3468
- OpenAlex
- W2292751194
- Cited by
- 69
- References
- 60
- FWCI
- 3.40
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.